Natco Pharma, Lupin alliance secures U.S. FDA nod for generic breast cancer drug

The U.S. Food and Drug Administration (U.S FDA) has approved Natco Pharma’s abbreviated caller cause exertion (ANDA) for crab cause Eribulin Mesylate Injection, 1 mg/2ml (0.5 mg/ml) single-dose vials, the generic drugmaker and its confederation spouse Lupin said connected Wednesday (June 3, 2026).

The approved merchandise is the bioequivalent to the notation listed cause (RLD) Halaven injection of Eisai Inc. The RLD (Halaven) had an estimated yearly income of $43.7 cardinal successful the U.S., the 2 companies said citing IQVIA MAT April 2026 numbers. Eribulin Mesylate injection is indicated for the attraction of adults with metastatic bosom cancer.